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Available online 14 February 2019Periodontitis and peri-implantitis are two characteristic examples where bacterial infections compromise the
healing of dental tissues. Drug eluting scaffolds are a potential solution to this problem but their fabrication re-
quires suitable biomaterials with signiﬁcant drug loading capacity and regenerative potential to support new tis-
sue formation. With this aim, porous β-pyrophosphate crystals having a micro-pore area of 2.59 m2/g and an
average pore diameter of 65 nm, have been obtained by the heat treatment of brushite (at 780 °C). To demon-
strate the drug loading potential of the mineral, experiments with chloramphenicol have been conducted.
After tests with four common bacteria, the drug loadedmineral was shown to have enhanced antibacterial prop-
erties, particularly towards E. coli (74% growth inhibition) and S. aureus (48% growth inhibition). Taking into ac-
count β-pyrophosphate's signiﬁcant role in hard tissue mineralisation and the capability to tailor crystal micro-
porosity characteristics by controlled heat treatment, the mineral can be considered as an ideal biomaterial for
localised drug delivery in dental applications.u83@gma
r Ltd. ThisCrown Copyright © 2019 Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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β-Pyrophosphate1. Introduction
Bacterial colonisation can have signiﬁcant implications for the
healing process of tissues. Two characteristic clinical conditions related
to bacterial contamination, are periodontitis (PD) and peri-implantitisil.com
is an open access article u(PI). PD is an inﬂammatory disease affecting the tissues that support
teeth. The disease begins when bacterial growth on a tooth surface
forms microbial plaque. An over-aggressive immune response against
this, leads to chronic inﬂammation of the periodontal tissues and the
destruction of the periodontal ligaments. If left untreated PD leads to
tooth loss [1] and current evidence also associates PD with other
systemic health conditions (e.g. cardiovascular diseases) [2]. Although
at the moment there are many treatment options available (e.g. soft
tissue grafts, bone replacement grafts, root modiﬁcation, growth/nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Minerals used and preparation method before drug loading.
Code Description Chemical
formula
Synthesis
DCPD Brushite CaHPO4·2H2O
Ca:P ratio = 1
Wet precipitation
D-DCPD Drug loaded brushite
DCP Monetite CaHPO4
Ca:P ratio = 1
Heat treatment of brushite
(200 °C, 2 h)D-DCP Drug loaded monetite
CPP1 β-pyrophosphate
β - Ca2P2O7
Ca:P ratio = 1
Heat treatment of brushite
(780 °C 2 h)D-CPP
Drug loaded
β-pyrophosphate
2 A.D. Anastasiou et al. / Materials and Design 168 (2019) 107661differentiation factors) most of them fail to provide restoration of peri-
odontal tissues because of the oral bacterial which are attached to the
tooth surface and contaminate any newly formed tissues [3–5]. PI on
the other hand, is deﬁned by infections around implants in orthopaedics
and regenerative dentistry [6]. Epidemiological studies suggest that be-
tween 12% and 43% of dental implantswill at somepoint develop symp-
toms of PI when in orthopaedics, and 2–5% of all implant related
procedures are likely to be compromised by bacterial infections [7].
In order to mitigate the risk of infection and to provide effective
treatment options to clinicians, researchers have focused their efforts
on the development of materials and scaffolds with the potential to in-
hibit bacterial growth. To that end, different strategies have been pur-
sued; porous materials (i.e. scaffolds and nanoparticles) with the
potential to be loaded with and subsequently release drugs ([8–10]),
surfaces with antibacterial properties ([11,12]) and biomaterials (e.g.
calcium phosphates) doped with ions known for their antibacterial ac-
tivity (e.g. Ag+, Ce3+) [13,14]. Drug eluting scaffolds, for localised
drug delivery during the entire cycle of healing, may be an effective op-
tion for dealingwith the aforementioned clinical conditions. The critical
step in this approach is the selection of a suitable biomaterial with sig-
niﬁcant drug loading capacity (for physical or chemical loading) and
the regenerative potential to support new tissue formation. In contrast
with well-known drug vehicles, which in most cases are polymeric
nanoparticleswith high resorption rates, this application requiresmate-
rials with lower dissolution rates (matching the healing rate of the
targeted tissue) in order to secure controlled drug delivery for longer
time periods. Based on these criteria, calcium phosphate minerals are
promising candidates for localised drug elution. Due to the structural
and chemical similarity with the natural mineral of human hard tissues
(i.e. carbonated hydroxyapatite), calcium phosphate biomaterials have
been extensively investigated for tissue engineering applications like
implant coatings, drug carrying vehicles, fabrication of scaffolds for
bone regeneration etc. Hydroxyapatite [HAP: Ca10(PO4)6(OH)2] is the
most popular of the apatites in clinical practice, however its effective-
ness as a bone graft material is disputable due to a number of factors
like brittleness and the extremely low rate of bioresorption [15]. β-
pyrophosphate (CPP:β-Ca2P2O7) is a promising alternative graftingma-
terial with good osteoconductive activity and better biodegradation
rates compared to HAP [16]. Recent studies demonstrate the impor-
tance of pyrophosphate ions to the mineralisation of bone (e.g. [17]).
Grover et al. [15] suggested that enzymatic action accelerates dissolu-
tion of the inorganic pyrophosphate ions causing a simultaneous loss
of mineralisation and localised rise in ion saturation and as a result the
presence of pyrophosphate can stimulate bone mineralisation and
healing. Themineral is biocompatible, non-toxic and found to have sim-
ilar mechanical properties to dental enamel whichmakes it suitable for
dental related applications (e.g. coating of dental implants) [18]. So far,
most of the published research regarding β-pyrophosphate, has been
focused on bioactivity and the regenerative potential of the mineral
and to the best of our knowledge, little work has been presented for py-
rophosphate as a drug delivery vehicle.
CPP crystals can be obtained by heat treatment of brushite (DCPD:
CaHPO4∙2H2O) in a temperature range between 750 and 850 °C. As
discussed in Anastasiou et al., [19], upon heating water is removed
from theDCPD structure resulting in the formation of extended porosity
at the surface of the ﬁnal CPP crystals. The aim of the current work is to
demonstrate the drug loading capacity of these porous pyrophosphate
crystals and the potential use of themineral as a localised drug delivery
system. Chloramphenicol (C11H12Cl2N2O5), a broad spectrum antibiotic
appropriate for treating a number of bacterial infections likemeningitis,
has been used for the experiments. Themodel drug has a toxic effect on
humanmitochondria resulting in bonemarrow suppression and in gen-
eral, is inappropriate for tissue engineering applications. However, it
was selected in this work as a demonstration drug because it is easy to
identify by spectroscopic techniques (i.e. FTIR, UV-VIS) and EDX map-
ping (due to the Cl in its structure). The antibacterial properties of thedrug loaded minerals, were evaluated following exposure to four com-
mon bacteria i.e. Escherichia coli, Staphylococcus aureus, Bacillus subtilis
and Bacillus cereus. The selection of the aforementioned bacteria was
based on their response towards chloramphenicol in order to prove
the release of the drug from the tested material i.e. is not directly rele-
vant to treatment of PD or PI.2. Materials and methods
The wet precipitation route that is described by Anastasiou et al.,
[18] was followed for the synthesis of the DCPD. 200 mL of a 0.1 M Ca
(NO3)2∙4H2O aqueous solution was heated to 37 °C, then a 0.1 M
(NH4)3PO4 solution (200 mL) was added drop by drop. The ﬁnal mix-
ture was left under continuous stirring at 37 °C for 2 h, then left to settle
for 1 h to allow precipitation. The DCPD crystals formed were collected
on a ﬁlter paper (Whatman grade 44 with pores of 3 μm), washed sev-
eral times with distilled water and dried for 24 h at 70 °C. For the prep-
aration of monetite (DCP: Ca2HPO4), DCPD powder was heat treated for
2 h at 200 °C. Similarly, β-pyrophosphate (CPP1) was prepared by
heating DCPD powder at 750 °C for 2 h.
To load the drug onmineral crystals the procedure described in [20]
was followed. 42 mg of chloramphenicol was introduced to 300 mL of
ultra-pure water and left to dissolve in an ultrasound bath for 40 min.
For each mineral, 70 mg of the corresponding powder was added to a
100 mL ﬂask and then ﬁlled with the dissolved drug solution resulting
in an initial concentration of 200 μg οf drug/mg of nanoparticles. The
ﬂasks were covered with aluminium foil to prevent any photo-
induced reactions and placed on stirring plates to keep the crystals dis-
persed. To determine the percentage of the drug loaded onto the min-
eral particles, the drug concentration remaining in the solution was
measured with a UV-VIS spectrometer (Perkin Elmer, LAMBDA 950)
multiple times during the incubation period. Before sampling (every
24 h), the stirring was interrupted to allow the minerals to settle for
1 h and then 5 mL (for each sample) was removed with a pipette
from the top layer of the solution. The samples were centrifuged for
20 min at 10,000 rpm (relative centrifugal force ~11,000g) in order to
separate any mineral crystals and then ﬁltered with Nylon syringe ﬁl-
ters. The concentration of the drug in each solution was determined
through spectroscopy measurements (UV-VIS) over a range of wave-
lengths between 200 and 400 nm, as described below. At the end of
the drug loading period themixture was left to settle for 1 h and the re-
maining solution was removed from the ﬂask with a 100 mL pipette.
The crystals of each mineral were collected in vials and frozen to−40
°C for 24 h, these were then freeze dried for 24 h to remove any mois-
ture. The same procedure was repeated in order to load CPP1 crystals
with a second drug, Doxycycline-hyclate (DOX) (CAS 24390-14-5, ac-
quired by Sigma Aldrich) which is more appropriate for treating PD
[21]. The CPP1 crystals loaded with DOX were tested for monitoring
the cumulative drug release over a period of 48 h by UV-VIS spectrom-
eter (Perkin Elmer, LAMBDA 950) measurement of the incubation solu-
tion (as per the loadingmeasurements for the chloramphenicol. The as-
synthesized and drug loaded materials used in the present work are
summarised in Table 1.
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Fig. 1. STA analysis of the initial brushite (DCPD) and identiﬁcation of the transformation
temperatures (the DSC curve is in blue and values are shown on the left y-axis while the
TGA curve is show in red and values re-ported on the right y-axis).
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Fig. 2. X-Ray diffraction patterns of the a) initial brushite; b) monetite obtained after
heating brushite at 200 °C for 2 h (with the peaks that do not match the reference
pattern); c) β-pyrophosphate minerals obtained after heating brushite at two different
temperatures (780 °C and 850 °C).
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were analysed by X-Ray powder diffraction using a Philips X'Pert
MPD, with monochromatic Cu Kα radiation (0.1541 nm). For the X-
Ray measurements, the step size was 0.065° and the 2θ scanning
range was from 10° to 65°. The data were collected over a period of ap-
proximately 25 min with a scan speed of 0.014° s−1.
Scanning electron microscopy (SEM, a Hitachi SU8230 1–30 kV cold
ﬁeld emission gun) was used to investigate the size and shape of the
powder crystals and to verify pore formation. Since calcium phosphate
minerals have poor electrical conductivity, prior to SEM each sample
was coated with a 5 nm thick layer of platinum and then vacuum
cleaned for 10 min. By removing the specimen-contamination we aim
to minimize the effect of electron beam induced hydrocarbon deposi-
tion and to reveal ﬁne surface features [22]. During the imaging of the
materials the range of the beam acceleration voltage was between 10
and 15 kV.
For TEM imaging, powder samples were dispersed in ethanol and a
drop of the suspension was placed onto a Lacey Carbon Film (Agar Sci-
entiﬁc Ltd). Imaging and analysis of the samples was performed with
a FEI Titan-cubed, Themis 300 Transmission Electron Microscope
(TEM) equipped with multiple HAADF/ADF/BF STEM detectors and a
FEI Super-X, 4-detector EDX system.
A Simultaneous Thermal Analyzer (PerkinElmer®, STA 8000) with
the capability of acquiring thermogravimetric analysis (TGA) and differ-
ential scanning calorimetry (DSC) was used to investigate the reactions
and phase changeswhich take place during the heating of thematerials.
All thermal experiments were carried out over a temperature range
from 30 to 1000 °C and at a heating rate of 20 °C/min.
Nitrogen adsorption/desorption experiments were performed for
the determination of the surface area (multi-point BET method), the
total pore volume (at P/Po = 0.99), and the pore size distribution
(BJH method using adsorption data) of the prepared microporous crys-
tals. The materials were ﬁrstly outgassed at 150 °C for 16 h under 6.6
×10−9mbar vacuum, using anAutomatic Volumetric SorptionAnalyzer
(Autosorb-1MP, Quantachrome). Measurements were carried out at
−196 °C.
The antibacterial activity of the mineral powders was evaluated
according to ISO 207043:2007 [20,23]. Bacterial strains of Escherichia
coli (BL21) and Bacillus subtilis were used as the model Gram-
negative bacteria while, strains of Staphylococcus aureus (ATCC
25923) and Bacillus cereus were used as Gram-positive bacteria.
Cells were grown in 100 mL of sterile nutrient broth (Luria-Bertani
broth, LB) at 150 rpm and 37 °C. They were collected at thelogarithmic stage of growth and the concentration of the suspen-
sions was adjusted to OD600 (optical density at 600 nm) value of
0.5 in 25 mM phosphate buffered saline solution (PBS, Sigma) before
incubation with the respective powder sample. Each mineral (before
and after drug loading) was tested for three different concentrations
namely 25, 50 and 100 μg/mL. After 24 h we measured the absor-
bance values at OD600 in triplicates and we obtained the mean
value for the reported data (average values ±SD).
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In Fig. 1 the characteristic thermogravimetric curve of brushite
(DCPD) for a temperature range between 30 and 1000 °C is presented.
As expected, three thermal incidents are identiﬁed that correspond to
the well documented phase transformations of the mineral [24]. The
ﬁrst occurs at 196 °C when DCPD loses two molecules of water and
transforms into monetite (CaHPO4; DCP). At 474 °C, DCP loses ½ H2O
and the formation of γ-pyrophosphate (γ-Ca2P2O7) takes place. Up to
this point the initial mass of the mineral is reduced by 25% due to
water removal and then remains stable at higher temperatures. In gen-
eral, pyrophosphates are compoundswithdichromate structure andde-
pending on the ﬁring temperature exist in three different forms (Bian
et al., 2004). γ-pyrophosphate is transformed to the beta form (β-
Ca2P2O7; CPP) after heating in a broad range of temperatures (between
600 and 900 °C). Aswe demonstrated in a previouswork [18], the trans-
formation intoα-pyrophosphate occurs at 1293 °C after which themin-
eral melts at 1380 °C.
2CaHPO4  2H2O
Brushite
→
−4H2O
196 °C
2CaHPO4
Monetite
→
−H2O
474 °C
γ‐Ca2P2O7
γ−pyrophosphate
→
600−900 °C
β‐Ca2P2O7
β−pyrophosphate
In Fig. 2a the powder diffraction pattern of the initial mineral, DCPD
is presented. The peaks from the obtained pattern match the reference
XRD data for brushite (01–074-6549) and this is the only detectable
phase. The intensity of the measured peaks at 2θ = 11.56 and 2θ =
23.51 is much higher than these predicted from the reference pattern.
Since both these peaks are parallel to the (0 1 0) plane, we can assumea)
c)
Fig. 3. SEM images of the differentminerals tested; a) initial brushite (DCPD); b)monetite crysta
after heating brushite at 780 °C (CPP1); d) pyrophosphate obtained after heating brushite at 8that the different intensity is due to texture of the crystals and that the
(0 1 0) plane is the preferred habit of the brushite powder. In Fig. 2b the
pattern for the material (DCP) heated at 200 °C is compared with the
reference data for monetite and all the characteristic peaks are identi-
ﬁed (e.g. at 2θ= 26.6, 29.3 and 32.6). In Fig. 2c the two minerals pro-
duced by heating DCPD at 780 °C (CPP1) and 850 °C (CPP2)
respectively, are compared with the reference pattern of β-
pyrophophate (04-009-8733). In both cases we can match all the
peaks with the reference and consequently both materials can be con-
sidered as β-Ca2P2O7. The only difference between the two patterns is
the relative intensity of the peak at 2θ= 29° which is much higher for
the CPP1 mineral. As discussed before for brushite, the higher intensity
can be attributed to texture and preferential growth of the crystals.
Heating at higher temperature results in the reordering of the pyro-
phosphate crystals and texture loss.
In Fig. 3, SEM images of the initial material and the products of
heat treatment are presented. As depicted in Fig. 3a, the brushite
crystals grow in the shape of 40 μm long platelets with thickness
around 1 μm. High magniﬁcation images show a homogenous sur-
face without any indications of porosity. After heat treatment at
200 °C and the transformation of brushite tomonetite, there is strong
evidence that the crystals retain their general platelet shape. The loss
of water of crystallisation during the transition from brushite
(CaHPO4·2H2O) to monetite (CaHPO4) is manifested in the appear-
ance of nano-pores and micro-structures (Fig. 3b) as a result of
molar volume change. The morphological change of the surface is
more apparent for CPP1 (produced by heating brushite at 780 °C)
where, extended porosity was identiﬁed (Fig. 3c). In this case, theb)
d)
ls (DCP) andnano-structures at the surface (in the red square); c) pyrophosphate obtained
50 °C for 5 h.
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Fig. 4. Pore diameter distribution of pyrophosphate (CPP1) and monetite (DCP) as
measured using gas adsorption porosimetry.
Table 2
Porosimetry results for initial brushite (DCPD), monetite (DCP) and β-pyrophosphate
(CPP1).
DCPD DCP CPP1
BET surface area, m2/g 11.8 27.8 13.2
Micro-pore area, m2/g 0 1.85 2.59
Pore size, nm – 10 65
5A.D. Anastasiou et al. / Materials and Design 168 (2019) 107661pores become larger in size due to the radical volume change be-
tween β-pyrophosphate and monetite and because of the reordering
and remineralisation of the pyrophosphate crystals. Prolonged heat
treatment above 780 °C (e.g. 850 °C for 5 h), changes completely
the morphology of the crystals and results in the formation of
smaller nuclei along the edge of the parent mineral (Fig. 3d). In this
case we can assume that the surface porosity is reduced and thus
no drug loading experiments have been performed for this material.
The initial brushite (DCPD) and the heat treatment products DPC
and CPP1, were tested with gas adsorption porosimetry to verify the in-
creased porositywhich is apparent in the SEM images. As is presented in
Table 2, the BET surface area for the initial DCPD was measured at
11.8 m2/g (also Fig. S1). Taking into account the micro pore volume
and themicro-pore areaweremeasured to be negligible, we can assume0 30 60 90 120 150 180
0
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 DCPD
 DCP
 CPP1
%,gnidaol
gur
D
Time, h
a)
Fig. 5. a) Percentage of loaded drug for three differentminerals. Fittingwithmono exponential
loaded pyrophosphate (D-CPP1). Fitting with a power law model (error bars 10%).that this overall value corresponds to the external surface area of the
crystals. For the case of DCP the BET surface area is dramatically in-
creased to 27.8 m2/g, with 1.85 m2/g of micro-pore area and the rest
the external surface area of monetite crystals. Although the crystals
size and shape remain the same during the transformation of brushite
to monetite, the increase of the external surface area is attributed to
the microstructures that are seen to emerge on the surface of the
monetite crystals (Fig. 3b). As these structures are seen to reduce in fre-
quency during the transformation of monetite to pyrophosphate, the
total BET surface area for the latter decreases to 13.2 m2/g. CPP1 how-
ever presents the highest micro-pore area (2.59 m2/g) with an average
pore diameter centred around 65 nm (Fig. 4).
Drug loading experiments were performed utilising chlorampheni-
col (CAM). As explained above the concentration of CAM in aqueous so-
lutions was determined using UV–VIS spectroscopy, by characterising
the intensity of the peak at 275 nm. Before the drug loading experi-
ments, eight control solutions with concentrations in the range of 1 to
150 ppmwere tested to obtain a calibration curve that links absorption
at 275 nmwith the drug's concentration in an aqueous solution (Fig. S2)
(based on the Lambert-Beer law). The drug loading percentage at differ-
ent drug loading periods (0 b t ≤ 168 h), was calculated according to
Eq. (1) and the results for each material incubated over a period of
168 h, and are presented in Fig. 5a.
Drug loading% ¼ Drug conc: t ¼ 0ð Þ−Drug conc: t ¼ xð Þ
Drug conc: t ¼ 0ð Þ  100 ð1Þ
In the case of DCPD (brushite) it was found that practically nodrug is
loaded on the crystals. Similar results were obtained for DCP (monetite)
forwhich itwas estimated that only 1.4% of the initial drug quantitywas
associatedwith themineral. However, in the case of CPP1 (β-pyrophos-
phate) the percentage of the loaded drug is increased dramatically to
8.5% over a total period of 168 h. As shown in Fig. 5a the loaded quantity
over time follows amono exponential model. After 72 h, 6.2% of the ini-
tial drug was already loaded on the CPP1 crystals and a plateau is
reached after 144 h (8.3% loaded drug). In order to get an insight into
the drug release proﬁle from CPP1 crystals, the cumulative drug release
of Doxycycline over a period of 48h has beenmonitored byUV-VIS. As is
presented in Fig. 5b almost 80% of the loaded drug is released after 48 h
(the corresponding drug loading curve is shown in Fig. S3).
In Fig. 6 the FTIR spectra of the drug (chloramphenicol) and the
drug-loaded minerals are compared. For chloramphenicol, the vibra-
tional peak of C_O appears at 1683 cm−1 and the peak at 1562 cm−1
is assigned to the N\\H bend. The peak at 1518 cm−1 is assigned to
NO2 asymmetric stretch and the broad band at 1411 cm−1 corresponds0
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Fig. 6. FTIR spectra of chloramphenicol, the drug loaded and initial minerals D-CPP1 and CPP1. Magniﬁed spectra for D-CPP1 at wavenumbers between 1300 and 2000 cm−1.
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assigned to aromatic C\\H bends [25]. In order to conﬁrm the loading
of the drug to the minerals, we tried to identify the aforementioned
peaks in the spectra of D-CPP1, D-DCP and D-DCPD. Pyrophosphate
peaks (due to -PO4−3 and P2O7−4 ions) appear at wavenumbers between
1150 and 450 cm−1 and overlapwith several peaks of chloramphenicol.
In the 1300 and 1800 cm−1 wavenumber range, where no peaks of py-
rophosphate are expected, six characteristic peaks of the drug were
identiﬁed at 1685, 1604, 1568, 1519, 1409 and 1348 cm−1, thereby ver-
ifying the presence of chloramphenicol in pyrophosphate crystals. In the
cases of D-DCP (drug loaded monetite) and D-DCPD (drug loaded
brushite) no FTIR vibrational drug peaks were identiﬁed for chloram-
phenicol (Fig. S4).
To further conﬁrm the presence of the drug on pyrophosphate crys-
tals, the CPP1 and D-CPP1 minerals were analysed by Transmission
Electron Microscopy (TEM) (Fig. 7). Chlorine was used as a marker
to identify the drug during EDXmapping since chloramphenicol con-
tains two Cl atoms in its molecule (C11H12Cl2N2O5) and Cl is not in-
volved at any stage of the mineral synthesis. As is presented in
Fig. 7a, the projected image of the initial CPP1 crystal shows the pres-
ence of 60–100 nm diameter pores running through the crystal
which is in agreement with the ﬁndings of SEM imaging (Fig. 3c)
and gas adsorption porosimetry (Fig. 4). As expected for this mate-
rial no evidence of Cl was found by EDX. In the case of D-CPP1, Cl is
identiﬁed both in elemental maps (Fig. 7b) and in area spectra
(Fig. 7c) and thus it is conﬁrmed that the crystals are loaded with
the drug. Even at higher magniﬁcation imaging it wasn't possible to
identify any chloramphenicol molecules on the surface of the crys-
tals and that suggests that the drug might have been encapsulated
within the pores of the mineral.
The antibacterial properties of the minerals D-CPP1, CPP1, D-DPC
and DPC have been evaluated after experiments with four common
bacteria. As depicted in Fig. 8a, the drug loaded pyrophosphate
(D-CPP1) results in signiﬁcantly higher inhibition of the bacterial
growth than the initial material (CPP1), particularly for the cases of
E. coli (74% for D-CPP1 and 40% for CPP1) and B. cereus (35% for
D-CPP1 and 18% for CPP1). For monetite, the drug loaded (D-DPC)
and initial mineral (DPC) demonstrated similar effect on bacterial
growth and the only statistically signiﬁcant difference were ob-
served for the case of E. coli (37% for D-DPC and 28.5% for DPC)
(Fig. 8b).4. Discussion
Porous pyrophosphate crystals have been formed by heating
brushite at 780 °C for 2 h. Although the porosity of the initial material
is negligible, the crystals that have been obtained after heating, have a
micro-pore area of 2.59 m2/g and an average pore diameter of 65 nm
(Table 2). Pore formation is the result of; a) the removal of water mole-
cules from the brushite crystal structure; b) the reordering and
remineralisation into pyrophosphate crystals (above 600 °C). The ﬁrst
phase transformation of brushite occurs at 196 °C when it loses two
water molecules and monetite is formed. The initial platelet like shape
is retained but the evolution of water results in the appearance of
nano-structures on the surface of monetite crystals and consequently
there is an increase of the external surface area (Fig. 3). Although
there is a dramatic increase of the total BET surface area, from
11.8 m2/g (value for brushite) to 27.8 m2/g (value for monetite), the
micro-pore surface area, which is important for drug encapsulation, is
only 1.87 m2/g (Table 2). In the case of β-pyrophosphate though, the
formation of porosity is a matter of crystal reordering and
remineralisation. As identiﬁed by thermogravimetric analysis of
brushite, the formation of β-pyrophosphate takes place in a broad
range of temperatures between 600 and 900 °C (Fig. 1). Depending on
the temperature and the duration of heat treatment, the extent of crystal
reordering is different and consequently the surface area and the poredis-
tribution vary. As an example, in Fig. 9, the SEM images of pyrophosphate
crystals obtained at different temperature and heating times are com-
pared. By increasing the heat treatment temperature, from 780 °C
(Fig. 9a) to 850 °C (Fig. 9b), it appears that thenumber of pores on the sur-
face of the crystals is increaseddramatically (heating time for both cases is
2 h). On the other hand, an increase in the heating time, from2 h (Fig. 9b)
to 6 h (Fig. 9c), results in the breakdown of the large platelet like crystals
and the formation of nano-crystals which are assumed to have negligible
surface or micro-porosity. These three examples are indicative of the po-
tential for controlling the micro-porosity in the resulting mineral phase
and consequently the drug loading capacity and potential drug release
rate of the mineral system. Depending on the needs of the ﬁnal applica-
tion the appropriate drug delivery system can be designed and formu-
lated by controlling the heat treatment conditions of brushite.
Although there is notmuchdifference between themeasuredmicro-
pore area of monetite (1.87m2/g for DCP) and that of β-pyrophosphate
(2.59m2/g for CPP1), the quantity of the loaded drug on the second case
7A.D. Anastasiou et al. / Materials and Design 168 (2019) 107661is much higher. This behaviour is attributed to the apparent large differ-
ence in the average pore size in the two minerals (centred around
10 nm for DCP and 65 nm for CPP1) since the drug loading procedure
followed in this work is based on the adsorption of the dissolved drug
onto the mineral particles.
The presence of loaded drug into the matrix of pyrophosphate crys-
tals is evident after experiments with four common bacteria. As
depicted in Fig. 8a, the drug loadedmaterial (D-CPP1) has enhanced an-
tibacterial activity over E. coli, B. cereus and S. aureuswhile, for B. subtilis
therewasn't any signiﬁcant difference between the effect of D-CPP1 and
CPP1. These results are reasonable if we consider that theminimum re-
quired concentration of chloramphenicol to inhibit bacteria growth, is
only 0.015 μg/mL for E. coli [26], and 14 μg/mL for B. subtilis [27]. In0 1 2
0.0
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Fig. 7. TEM images and EDX analysis of pyrophosphate crystals before and after drug loading; a
crystals (D-CPP1) and EDX maps for Ca and Cl; c) EDX spectrum of the drug loaded crystals anthe case of monetite although there is a trend that indicates better anti-
bacterial behaviour of the drug loaded mineral (D-DCP) this is not sta-
tistically signiﬁcant and could be the result of residual drug on the
surface of the crystals. In previous works, β-pyrophosphate proved a
suitable biomaterial for dental related applications based on its similar-
ity with dental enamel [11] (in terms of mechanical properties and sta-
bility in the acidic environment of oral cavity) and its signiﬁcant role in
the remineralisation of hard tissues [15].
5. Conclusion
In thisworkwe investigated the potential use ofβ-pyrophosphate as
a localised drug delivery system. Porous pyrophosphate crystals have3 4 5
from area #1 
Ca
Cl
P
rgy, (Kev)
Ca Cl
1 μm
) TEM images of the initial CPP1 crystals; b) TEM image of the drug loaded pyrophosphate
d identiﬁcation of the Cl peak at 2.6 KeV (the spectrum of CPP1 is presented in Fig. S5).
Fig. 8. Effect of drug loaded and initial minerals on the growth of four common bacteria; a) Pyrophosphate (CPP1) and drug loaded pyrophosphate (D-CPP1) crystals (100 μg/mL);
b) Monetite (DCP) and drug loaded monetite (D-DCP) crystals (100 μg/mL). *Signiﬁcant statistical difference between the drug loaded and the initial β-pyrophosphate by 2 sample t-
test (*p b 0.05, ***p b 0.001).
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Fig. 9. Surfacemorphology of pyrophosphate crystals for three different heating conditions; a) 780 °C and 2 h heating time; b) 850 °C and 2 h heating time; c) 850 °C and 6 h heating time.
8 A.D. Anastasiou et al. / Materials and Design 168 (2019) 107661been obtained by the heat treatment of brushite and a broad spectrum
antibiotic, i.e. Chloramphenicol, has been used to demonstrate the
drug loading capacity of the resultingmineral. The enhanced antibacte-
rial properties of the drug loaded pyrophosphate have been proven by
tests with four common bacteria.
During the transition from brushite to β-pyrophosphate (via in-
termediate phases of monetite and γ-pyrophosphate) porosity is
formed at the surface of the crystals due to; a) water removal from
the initial structure; b) break down and reordering of the pyrophos-
phate crystals. By controlling the conditions of brushite heat treat-
ment (temperature and heating period) it is possible to control the
micro-porosity characteristics of the ﬁnal mineral and consequently
to design a suitable drug delivery system based on the demands of
each application.
The drug loading potential of β-pyrophosphate in combination with
its signiﬁcant role in hard tissuemineralisationmake it a promisingma-
terial for dealing with signiﬁcant clinical conditions where bacterial
contamination is a critical problem, for example peri-implantitis and
periodontitis.
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